Theralase Photo Dynamic Compounds Effective in Destruction of Drug Resistant Bacteria

1. Theralase Photo Dynamic Compounds Effective in Destruction
of Drug Resistant Bacteria
Toronto, Ontario – October 17, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced
today that its Photo Dynamic Compound (PDC) technology has been proven effective in the
destruction of staphylococcus aureus and its multi drug resistant strain, methicillin resistant
staphylococcus aureus, also known as MRSA.
MRSA is a bacteria strain that has grown resistant to antibiotics and hence has the potential of
causing invasive infections, which are extremely difficult to treat in 25% of the population
infected. In 2005, the Centers for Disease Control and Prevention reported that 94,000
individuals were hospitalized as a result of MRSA infections and there were 18,650 deaths as a
result, costing the US healthcare system an additional $45 billion a year.
The scientific data supporting this discovery was presented yesterday at the 9th International
Symposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held in Brixen,
Italy. The presentation by Dr. Lothar Lilge confirms the significance of the research conducted
by Theralase’s and University Health Network’s (UHN) scientists.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. stated that, “Theralase unveiled to
the scientific community its advanced sterilization platform technology that is able to deliver an
8 log or 99.999999% kill rate, which is comparable with complete sterilisation of life threatening
infectious microorganisms, such as staphylococcus aureus and MRSA. Theralase’s new PDC
technology would therefore be well suited to preventing hospital acquired infections, as well as
infections found in nursing homes, schools or bacterial contaminations in food processing
facilities. Quite simply, once MRSA bacteria have been detected, they could be quickly
destroyed utilizing Theralase’s patented Photo Dynamic Compounds and proprietary light
sources.”
Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute / Princess Margaret Cancer Centre,
UHN stated, “Theralase’s PDCs in conjunction with light exposure were shown to achieve
essentially complete sterilization, even at low concentrations, against staphylococcus aureus
and MRSA in an in vitro laboratory setting. The effective dose of tested PDCs was not toxic for
human tissues even after 4 hours of incubation demonstrating their suitability and safety to
sterilization applications. As an added benefit, the Theralase PDCs maintained their sterilizing
activity even in low oxygen conditions demonstrating a Type I photosensitization effect that
may open up new opportunities for the safe and effective destruction of many strains of deadly
organisms and tumours that thrive in low oxygen environments, such as cancer.”
Dr. Arkady Mandel went on to say, “The dramatic increase of antibiotic resistance in bacteria
has led me to investigate whether Theralase’s PDCs would be effective in the destruction of
MRSA, as an alternative to antibacterial pharmaceutical drugs. Our successes to date will allow
Theralase’s PDCs to be used in the future to combat difficult to heal invasive infections. The

2. Theralase PDCs in these studies have been chosen for their low dark toxicity to human tissue
and for their high cancer and bacteria targeting properties. The Theralase PDCs are extremely
promising for the development of advanced disinfection and sterilization strategies for
controlling and eliminating hospital and community acquired infections, such as MRSA.”
Roger Dumoulin-White, President and CEO of Theralase stated, “Based on our recent successes
with our PDC technology in destroying MRSA, Theralase is actively pursuing early
commercialization of this technology through strategic partnerships to co-develop the
technology for particular sterilization applications. As an added benefit, due to the very low
concentrations of PDCs required for sterilization, the costs of administering this technology will
be very cost effective. The early commercialization of our patented PDC technology with
strategic partners will dramatically improve the financial revenues of the organization. These
scientific studies thus highlight Theralase’s commitment to advancing its exclusive patented
technologies for the ultimate goal of greater commercial opportunities for the Company.”
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets
patented, superpulsed laser technology utilized in biostimulation and biodestruction
applications. Theralase technology is safe and effective in treating pain, inflammation and for
tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is
currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and
destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and
patented laser technology.
For further information please visit www.theralase.com, regulatory filings may be viewed by
visiting www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-
looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any
obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & Chief Executive Officer
416-447-8455 ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com
Arkady Mandel

3. Chief Scientific Officer
416-447-8455 ext. 242
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262
gbewsh@theralase.com